Tosin noted
Ali Rezaie, Medical Director of Gastroenterology Motility at Cedars-Sinai Medical Center, emphasized the need for context, noting that while the relative risk increases by 33%, the absolute risk remains low at 0.2%
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D
The study, published Monday in the journal Nature Medicine, is one of the first big-picture looks at the benefits and risks of these new drugs, which rapidly made an impact on health care, insurance coverage, the grocery industry, and even the economy of an entire country (Denmark, where Novo Nordisk, the maker of Ozempic and Wegovy is based.) These drugs have also been given partial credit for a recent dip in obesity rates in the US, which dropped in 2023 for the first time in over a decade
32 , e4619 (2023)
For patients without neurological involvement, the initial regimen is typically 1 mg intramuscularly three times weekly for 2 weeks